May & Baker Nigeria Plc manufactures, sells, and distributes human pharmaceuticals, human vaccines, and consumer products in Nigeria.
Price History & Performance
|Historical stock prices|
|Current Share Price||₦4.36|
|52 Week High||₦3.05|
|52 Week Low||₦5.18|
|1 Month Change||-2.46%|
|3 Month Change||-1.58%|
|1 Year Change||45.33%|
|3 Year Change||85.53%|
|5 Year Change||431.71%|
|Change since IPO||225.55%|
Recent News & Updates
|MAYBAKER||NG Pharmaceuticals||NG Market|
Return vs Industry: MAYBAKER exceeded the NG Pharmaceuticals industry which returned 39.5% over the past year.
Return vs Market: MAYBAKER exceeded the NG Market which returned 40.4% over the past year.
Stable Share Price: MAYBAKER is not significantly more volatile than the rest of NG stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: MAYBAKER's weekly volatility (5%) has been stable over the past year.
About the Company
May & Baker Nigeria Plc manufactures, sells, and distributes human pharmaceuticals, human vaccines, and consumer products in Nigeria. It operates through Pharmaceuticals and Beverage segments. The company offers pharmaceuticals, including anti-diabetic; anti-hypersensitive; anti-infective; anti-malaria; analgesic; cough and cold; anxiolytics; and nature care products.
May & Baker Nigeria Fundamentals Summary
|MAYBAKER fundamental statistics|
Is MAYBAKER overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|MAYBAKER income statement (TTM)|
|Cost of Revenue||₦6.32b|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||0.63|
|Net Profit Margin||9.97%|
How did MAYBAKER perform over the long term?See historical performance and comparison
6.9%Current Dividend Yield
Is May & Baker Nigeria undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: MAYBAKER (NGN4.36) is trading above our estimate of fair value (NGN2.37)
Significantly Below Fair Value: MAYBAKER is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: MAYBAKER is good value based on its PE Ratio (7x) compared to the African Pharmaceuticals industry average (9.7x).
PE vs Market: MAYBAKER is good value based on its PE Ratio (7x) compared to the NG market (7.4x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MAYBAKER's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MAYBAKER is good value based on its PB Ratio (1.1x) compared to the XF Pharmaceuticals industry average (1.5x).
How is May & Baker Nigeria forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as May & Baker Nigeria has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has May & Baker Nigeria performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MAYBAKER has high quality earnings.
Growing Profit Margin: MAYBAKER's current net profit margins (10%) are lower than last year (10.7%).
Past Earnings Growth Analysis
Earnings Trend: MAYBAKER's earnings have grown significantly by 39.3% per year over the past 5 years.
Accelerating Growth: MAYBAKER's earnings growth over the past year (24.4%) is below its 5-year average (39.3% per year).
Earnings vs Industry: MAYBAKER earnings growth over the past year (24.4%) exceeded the Pharmaceuticals industry 10%.
Return on Equity
High ROE: MAYBAKER's Return on Equity (15.9%) is considered low.
How is May & Baker Nigeria's financial position?
Financial Position Analysis
Short Term Liabilities: MAYBAKER's short term assets (NGN9.0B) exceed its short term liabilities (NGN3.5B).
Long Term Liabilities: MAYBAKER's short term assets (NGN9.0B) exceed its long term liabilities (NGN3.9B).
Debt to Equity History and Analysis
Debt Level: MAYBAKER's debt to equity ratio (61.5%) is considered high.
Reducing Debt: MAYBAKER's debt to equity ratio has reduced from 93.8% to 61.5% over the past 5 years.
Debt Coverage: MAYBAKER's debt is not well covered by operating cash flow (10.3%).
Interest Coverage: MAYBAKER's interest payments on its debt are well covered by EBIT (5x coverage).
What is May & Baker Nigeria current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: MAYBAKER's dividend (6.88%) is higher than the bottom 25% of dividend payers in the NG market (3.28%).
High Dividend: MAYBAKER's dividend (6.88%) is low compared to the top 25% of dividend payers in the NG market (7.27%).
Stability and Growth of Payments
Stable Dividend: Whilst dividend payments have been stable, MAYBAKER has been paying a dividend for less than 10 years.
Growing Dividend: MAYBAKER's dividend payments have increased, but the company has only paid a dividend for 4 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (47.9%), MAYBAKER's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Mr. Patrick Ajah serves as Managing Director, Chief Executive Officer and Executive Director at May & Baker Nigeria plc since January 01, 2021. He is a passionate and visionary leader with over two decades...
Experienced Board: MAYBAKER's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
May & Baker Nigeria plc's employee growth, exchange listings and data sources
- Name: May & Baker Nigeria plc
- Ticker: MAYBAKER
- Exchange: NGSE
- Founded: 1944
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: ₦7.522b
- Shares outstanding: 1.73b
- Website: https://www.may-baker.com
Number of Employees
- May & Baker Nigeria plc
- Industrial Estate
- 3/5 Sapara Street
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/21 20:59|
|End of Day Share Price||2021/10/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.